Earlier this year at the annual JP Morgan Healthcare conference--and about a month after the company announced that it would sell out to Merck for $8.4 billion--Cubist Pharmaceuticals started giving away decks of "Cards Against Biotechnology." A biotech-themed version of Cards Against Humanity, the game was a crowd-pleaser.
Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.
The scoop behind Cubist Pharmaceuticals' Cards Against Biotechnology, a hard-to-explain favor from a surreal party.
Cubist Pharmaceuticals picked up FDA approval for its latest antibiotic contender, a potential blockbuster whose promise helped bring Merck to the table with a $9.5 billion buyout offer.
Merck is shelling out $9.5 billion for antibiotics specialist Cubist Pharmaceuticals, joining the wave of major drugmakers with a renewed interest in anti-infectives.
After 11 years at the helm of Cubist Pharmaceuticals, CEO Michael Bonney is stepping down and handing the reins to COO and President Robert Perez.
The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.
Antibiotics development is about to get a much-need boost with the release of new federal proposals aimed at curbing rising antimicrobial resistance infections caused by so-called superbugs.
Big Pharma has largely exited the antibiotics arena in the past several years, contributing to the dearth of products in the global pipeline as rising antimicrobial resistance becomes a very real public health threat.
Lexington, MA's Cubist Pharmaceuticals is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.